Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;20(3):218-33.

Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth

Tamara Pringsheim  1 , Constadina Panagiotopoulos, Jana Davidson, Josephine Ho; CAMESA guideline group
Collaborators, Affiliations

Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth

Tamara Pringsheim et al. J Can Acad Child Adolesc Psychiatry. 2011 Aug.

Erratum in

  • J Can Acad Child Adolesc Psychiatry. 2011 August;20(3):1–2.
  • Errata.
    [No authors listed] [No authors listed] J Can Acad Child Adolesc Psychiatry. 2011 Nov;20(4):328-9. J Can Acad Child Adolesc Psychiatry. 2011. PMID: 22114616 Free PMC article.

Abstract

Background: The use of antipsychotics, especially second generation antipsychotics (SGAs), for children with mental health disorders in Canada has increased dramatically over the past five years. These medications have the potential to cause major metabolic and neurological complications with chronic use.

Objective: Our objective was to synthesize the evidence for specific metabolic and neurological side effects associated with the use of SGAs in children and make evidence-based recommendations for the monitoring of these side effects.

Methods: We performed a systematic review of controlled clinical trials of SGAs in children. Recommendations for monitoring SGA safety were made according to a classification scheme based on the GRADE system. When there was inadequate evidence to make recommendations, recommendations were based on consensus and expert opinion. A multi-disciplinary consensus group reviewed all relevant evidence and came to consensus on recommendations.

Results: Evidence-based recommendations for monitoring SGA safety are provided in the guideline. The strength of recommendations for specific physical examination maneuvers and laboratory tests are provided for each SGA medication at specific time points.

Conclusion: Multiple randomized controlled trials (RCTs) have established the efficacy of many of the SGAs in pediatric mental health disorders. These benefits however do not come without risk; both metabolic and neurological side effects occur in children treated with these SGAs. The risk of weight gain, increased BMI and abnormal lipids appears greatest with olanzapine, followed by clozapine and quetiapine. The risk of neurological side effects of treatment appears greatest with risperidone, olanzapine and aripiprazole. Appropriate monitoring procedures for adverse effects will improve the quality of care of children treated with these medications.

PubMed Disclaimer

References

    1. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Group RDBS. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. The American Journal of Psychiatry. 2002;159(8):1337–1346. - PubMed
    1. American Diabetes Association, A. P. A. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27(2):596–601. - PubMed
    1. Anderson G, Scahill L, McCracken J, McDougle C, Aman M, Tierney E, Vitiello B. Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. Biological Psychiatry. 2007;61(4):545–550. - PubMed
    1. Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Moreno D. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. European Child & Adolescent Psychiatry. 2009;18(7):418–428. - PubMed
    1. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. Journal of the American Academy of Child & Adolescent Psychiatry. 2007;46(5):558–565. - PubMed

LinkOut - more resources